Cardiovascular Disorders

1.    Koh SJ et al. Association of serum RANTES concentrations with established cardiovascular risk markers in middle-aged subjects. Int J Cardiol 2008. (Epub ahead of print).
2.    Leu HB et al. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein. Chest 2004;126:1032-9.
3.    Romero-Corral A et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med 2008. (Epub ahead of print).
4.    Thorand B et al. Association of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women. Results from the MONICA/KORA Augsburg Study. Thromb Haemost 2006;95:134-41.
5.    Demerath E et al. The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001;28:664-78.
6.    Apostolakis S et al. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovasc Hematol Agents Med Chem 2008;6:150-8.
7.    Kanda T et al. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004;45:183-93.
8.    Busch G et al. Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005;25:461-6.
9.    Tiret L et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112:643-50.
10.    Kobayashi M et al. Expression of monocyte chemoattractant protein-1 in idiopathic dilated cardiomyopathy. Int J Cardiol 2008;126:427-9.
11.    Brevetti G et al. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J 2008;29:224-30.
12.    Nicholls SJ et al. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25:1102-11.
13.    Dabek J et al. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'. Pharmacol Rep 2006;58:799-805.
14.    Ueland T et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol 2005;46:2018-21.
15.    Piemonti L et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003;26:2883-9.
16.    San Miguel Hernández A et al. Soluble CD40 ligand: a potential marker of cardiovascular risk. Rev Clin Esp 2007;207:418-21.
17.    Bellisarii FL et al. Tumor necrosis factor-alpha and cardiovascular diseases. Ital Heart J 2001;2:408-17.
18.    Riksen NP et al. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 2008;29:258-67.
19.    Jie KE et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006;291:F932-44.
20.    Toyozaki T et al. Levels of soluble Fas ligand in myocarditis. Am J Cardiol 1998;82:246-8.
21.    Charash WE et al. Plasma fibronectin levels during cardiopulmonary bypass. J Appl Physiol 1990;69:1644-50.
22.    van Kimmenade RR et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24.
23.    Cesari M et al. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol 1999;19:1378-86.
24.    Osterlund B et al. Impaired myocardial t-PA release in patients with coronary artery disease. Acta Anaesthesiol Scand 2008;52:1375-84.
25.    Andresen TK et al. Soluble VCAM-1 is a very early marker of endothelial cell activation in cardiopulmonary bypass. Perfusion 2002;17:15-21.
26.    Kappelmayer J et al. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004;42:475-86.
27.    Chung I et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 2009;41:45-51.
28.    Lyon CJ et al. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003;115 Suppl 8A:62S-68S.
29.    Haught WH et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996;132(1 Pt 1):1-8.